Winton Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-47,635
Closed -$727K 928
2025
Q3
$727K Buy
+47,635
New +$620K 0.03% 518

Other funds holding AVDL

Winton Group's AVDL Position: Q4 2025 in Review

Winton Group sold out of Avadel Pharmaceuticals (AVDL) in Q4 2025, closing a stake of 47,635 shares — an estimated $727K sold.

Winton Group first reported a position in AVDL in Q3 2025 and held it in 1 quarter. The position peaked at $727K in Q3 2025. 207 funds tracked by Wall St. Rank hold AVDL as of Q4 2025.

  • Winton Group reported no remaining Avadel Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Winton Group sold 47,635 Avadel Pharmaceuticals shares in Q4 2025, an estimated $727K.
  • Winton Group first reported a position in Avadel Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Winton Group's Avadel Pharmaceuticals position peaked at $727K in Q3 2025.
  • 207 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2025.

Based on Winton Group's 13F filing for Q4 2025, filed 11 Feb 2026.